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Abstract
Transcriptional repressors and corepressors play a critical role in cellular homeostasis and are frequently altered in
cancer. C-terminal binding protein 1 (CtBP1), a transcriptional corepressor that regulates the expression of tumor sup-
pressors and genes involved in cell death, is known to play a role in multiple cancers. In this study, we observed the
overexpression and mislocalization of CtBP1 in metastatic prostate cancer and demonstrated the functional signifi-
cance of CtBP1 in prostate cancer progression. Transient and stable knockdown of CtBP1 in prostate cancer cells
inhibited their proliferation and invasion. Expression profiling studies of prostate cancer cell lines revealed thatmultiple
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tumor suppressor genes are repressed by CtBP1. Furthermore, our studies indicate a role for CtBP1 in conferring
radiation resistance to prostate cancer cell lines. In vivo studies using chicken chorioallantoic membrane assay,
xenograft studies, and murine metastasis models suggested a role for CtBP1 in prostate tumor growth and metas-
tasis. Taken together, our studies demonstrated that dysregulated expression of CtBP1 plays an important role in
prostate cancer progression and may serve as a viable therapeutic target.
Neoplasia (2012) 14, 905–914
Introduction
Transcriptional corepressor C-terminal binding protein 1 (CtBP1) is
known to play a crucial role in cellular homeostasis by regulating the
expression of numerous genes [1]. CtBP1 binds to and modulates the
activities of several transcription factors such as BKLF, FOG 1 and 2,
ZEB, EVI-1, and Zinc finger protein IKAROS among others [2].
DNA-binding proteins recruit CtBP1 through the PLDLS motif, origi-
nally identified in adenovirus early region 1A (E1A) protein [2,3].
Studies have shown that CtBP1 has NAD-dependent dehydrogenase
activity and forms repressive complexes with other proteins [4,5].
The enzymatic function of CtBP1 makes it an attractive therapeutic
target. Whereas the precise mechanism of CtBP1-mediated transcrip-
tional repression is unclear, studies suggest that it may involve histone
deacetylases (HDACs) that remove acetyl groups from histone tails,
enabling chromatin condensation and repression of gene expression
[6,7]. CtBP1 has also been shown to interact with the polycomb
group (PcG) transcriptional repressor HPC2 [8]. In Drosophila, CtBP
was reported to regulate the expression of intergenic transcripts that
regulate DNA binding by PcG proteins [9], providing a link between
CtBP1 and PcG member histone methyltransferase EZH2, which
is overexpressed in a wide variety of aggressive tumors including
prostate cancer [10]. A considerable amount of evidence suggests a
critical role for CtBP1 in tumor growth and epithelial-mesenchymal
transition [11]. One well-characterized target of CtBP1-mediated tran-
scriptional repression is the tumor suppressor and cell adhesion mole-
cule E-cadherin [12–15]. In myeloid leukemia cells, EVI-1–mediated
transformation is abrogated when its CtBP1 binding motifs are mu-
tated, implicating a role for CtBP1 in promoting oncogenesis in these
cancers [16]. In breast cancer, CtBP1 suppresses apoptosis and pro-
motes cell cycle progression [17], and a recent study indicated that
most of the invasive ductal breast cancer cases were CtBP1-positive
compared to normal breast tissue [18]. Furthermore, in pituitary tumor
cells, knockdown of CtBP1 resulted in reduced cell proliferation [19].
Whereas these studies suggest an oncogenic role for CtBP1, a detailed
molecular mechanism of CtBP1-mediated tumorigenesis has not been
explored in prostate cancer.
In the present study, we validated the overexpression of CtBP1 and
characterized its role in prostate cancer progression. Gene expression
studies using RNA from CtBP1-modulated prostate cell lines identi-
fied targets of CtBP1-mediated repression. Knockdown studies demon-
strated that CtBP1 expression is essential for prostate cancer cell growth
and proliferation as well as reactivation of the target tumor suppressors.
Removal of CtBP1 reduced cell survival and sensitized aggressive pros-
tate cancer cells to radiation. Importantly, our in vivo studies uncovered
a critical role for CtBP1 in prostate cancer growth and tumor metas-
tasis. Overall, our investigations indicate that CtBP1 plays an essential
role in prostate cancer progression and warrants consideration as a
valuable therapeutic target.
Materials and Methods
Expression Analysis
CtBP1 gene expression data were procured from cDNA microarray
analysis [20]. To measure the CtBP1 transcript levels, total RNA was
isolated from prostate cell lines and prostate tissue samples using the
RNeasy Mini Kit (Qiagen, Valencia, CA). Quantitative polymerase chain
reaction (qPCR) was performed as described [21]. All primers were syn-
thesized by Integrated DNATechnologies, Coralville, IA. PCR reactions
were performed in triplicates. Primer sequences used in the present study
includeCtBP1: F, TCACAGGCCGGATCCCAGACAGandR,GGT-
ACCTATAGGCAGCCCCATTGAGC and F, CCGTCAAGCAGA-
TGAGACAA and R, GGCTAAAGCTGAAGGGTTCC; E cadherin:
F, GGAGGAGAGCGGTGGTCAAA and R, TGTGCAGCTGGCT-
CAAGTCAA; ARHGDIB: F, ACAGGACTGGGGTGAAAGTG and
R, GAGCCTCCTCAACTGGAGTG; LCN2: F, CAAGGAGCTGA-
CTTCGGAAC and R, TACACTGGTCGATTGGGACA.
For immunoblot analysis, 10 μg of normal and prostate cancer
tissues as well as prostate cancer cell line lysates was boiled in sample
buffer, separated by sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis, and transferred onto polyvinylidene difluoride membrane
(GE Healthcare, Piscataway, NJ). The membrane was incubated for
1 hour in blocking buffer (TBS, 0.1% Tween, 5% nonfat dry milk)
and incubated overnight at 4°C with respective primary antibodies,
and signals were visualized after incubating with secondary antibody
conjugated with HRP. Densitometric scan of the immunoblot was
performed using ImageJ. The following antibodies and dilutions were
used for the immunoblots: anti-CtBP1 (1:2000 in blocking buffer, BD
Biosciences [San Jose, CA], Cat. No. 612042,), anti-LCN2 (1:10,000,
R&D Systems [Minneapolis, MN], Cat. No. AF1757), phospho-H2AX
(1:2000,Millipore [Billerica, MA], Cat. No. 16-202A), anti–β-actin mouse
monoclonal antibody (1:20,000, Sigma [St Louis, MO], Cat. No. A5316-
500ul), glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody
(1:5000, Abcam [Cambridge, MA], Cat. No. ab8245), and β-tubulin
(1:2000, Santa Cruz Biotechnology [Santa Cruz, CA], sc-9104).
Immunohistochemistry
Benign and prostate cancer tissues were obtained from the radical
prostatectomy series at the University of Michigan and from the
Rapid Autopsy Program, both part of the Michigan Prostate SPORE
Tissue Core. Institutional Review Board approval was obtained
to procure and analyze the tissues used in this study. Immuno-
histochemistry was carried out using standard biotin-avidin complex
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to evaluate CtBP1 expression using mouse monoclonal antibody against
CtBP1 (BD Biosciences) as well as a rabbit polyclonal antibody [22].
RNA Interference
Small interfering RNA (siRNA) duplexes for RNA interference
of CtBP1 was purchased from Dharmacon, Lafayette, CO (Thermo
Scientific, Cat. No. LQ-008609-00-0002). Short hairpin RNA (shRNA)
constructs were generated using pGreen-puro vector for two of the most
efficient siRNA duplexes by SBI (System Biosciences, Mountain View,
CA). Lentivirus for the stable knockdown of CtBP1 was generated
by the University of Michigan Vector Core. To perform the siRNA
knockdown, we plated prostate cancer cell lines DU145, PC3, and
LNCaP at 2 × 105 cells per well in a 6-well plate for immunoblot anal-
ysis and cell proliferation analysis and at 1.5 × 103 cells per well in a
Figure 1. Identification of CtBP1 overexpression in prostate cancer (PCa). (A) CtBP1 expression in the prostate cancer gene expression
profiling study. Data were obtained from benign, prostate cancer, and metastatic prostate cancer (MET) tissue expression profiling.
(B) Real-time qPCR of CtBP1 transcripts in benign and prostate cancer. Ratio was calculated relative to GAPDH. The boxes extend from
the lower to the upper quartile of the data, and whiskers extend to the most extreme data point that is no more than 1.5 times the
interquartile range from the box. Points beyond this range are shown as black dots. (C) Expression of CtBP1 protein in prostate cancer.
Extracts from prostate specimens were assessed for expression of CtBP1 by immunoblot analysis. β-Actin was used as a loading control.
(D) Immunohistochemical analysis of CtBP1 in prostate cancer. Left, benign prostate epithelia exhibiting nuclear staining. Localized prostate
cancer exhibiting nuclear and cytoplasmic staining. Metastatic prostate cancer shows increased cytoplasmic CtBP1 staining.
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96-well plate for Cell Titer-Glo (Promega, Madison, WI) proliferation
assays. Twelve hours after plating, the cells were transfected with siRNA
duplex, using Oligofectamine (Invitrogen, Carlsbad, CA). A second
identical transfection was performed 24 hours later. Sixty-four hours
after the first transfection, the cells were harvested for RNA isolation
or lysed for immunoblot analysis. For knockdown of LCN2 (NGAL),
specific siRNA (Dharmacon, Cat. Nos J-003679-07 and J-003679-09)
were used in DU145 and PC3 stable CtBP1 knockdown cells.
Figure 2. CtBP1 plays a role in cell proliferation and invasion. (A) Knockdown of CtBP1 in prostate cancer cell lines. Immunoblot analysis
using lysates from aggressive prostate cell lines DU145 and PC3 treated with two CtBP1-specific shRNA lentivirus and nontargeting
control lentivirus. β-Actin was used as control. (B, C) Knockdown of the CtBP1 reduces prostate cancer cell proliferation. Cell prolifer-
ation was measured using cells transduced with CtBP1 shRNA duplex or control nontargeting shRNA using DU145 and PC3 cells. (D, E)
Knockdown of the CtBP1 reduces prostate cancer invasion. DU145 and PC3 cells in which CtBP1 was stably knocked down using two
specific shRNA lentivirus against CtBP1 were used in Boyden chamber matrigel invasion assay. Nontargeting shRNA lentivirus served as
control. Invaded cells were stained and absorbance was measured.
Figure 3. CtBP1 knockdown reactivate tumor suppressors in prostate cancer. (A) Heat map of genes that are significantly altered by CtBP1
stable knockdown in LNCaP, PC3, and DU145 cells. Log2(Cy5/Cy3) ratios are shown for each expression array. Red and green represent
upregulated and downregulated genes, respectively, in CtBP1 knockdown cells, relative to the median of the reference pool. Black signifies
no change in expression. Known and putative tumor and metastasis suppressors are indicated in red letters. The color bar indicates the
fold change; red denotes up-regulation and green represents down-regulation. (B) CtBP1 regulates expression of E-cadherin. E-cadherin
expression was measured in CtBP1 stable knockdown DU145 cell lines and compared to control cell lines by qPCR. (C and D) CtBP1 regu-
lates expression of LCN2. LCN2 expression was measured in CtBP1 stable knockdown DU145 and PC3 cell lines by qPCR and immunoblot
analysis. (E) LCN2 knockdown in stable CtBP1 knockdown PC3 cells. Expression of LCN2 and CtBP1 were tested by immunoblot. (F) LCN2
knockdown enhances invasion. LCN2 was targeted by two independent specific siRNA in stable CtBP1 knockdown PC3 cell line, and
invasion experiment was performed using Boyden chamber matrigel assay (photomicrographs are shown in the inset; blue staining
represents invaded cells).
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Gene Expression Analysis of CtBP1 Knockdown Cells
RNA isolated from shRNA knockdown DU145, PC3, and LNCaP
as well as nontarget control cells were used for gene expression pro-
filing. Expression profiling was performed using the Agilent Whole
Human Genome Oligo Microarray (Agilent, Santa Clara, CA) according
to the manufacturer’s protocol. Statistical analysis of gene expression
array was performed. Microarray probes were identified as differential
on CtBP1 knockdown if the mean log2(Cy5/Cy3) ratio across cell lines
was significantly different from zero as measured by one-sample two-
sided Student’s t tests, using a P-value cutoff of .05. The list of differ-
entially expressed genes was additionally filtered such that the mean
log2(Cy5/Cy3) ratio exceeded log2(2.5) in absolute value. The resulting
list of 155 genes are shown in Figure 3A as a heat map and listed in
Table W1. Statistical analysis was performed using R (www.r-project.
org), version 2.15.0.
Cell Proliferation Assays
For cell counts at 96 and 120 hours, the cells were treated with
trypsin and replated in six-well dishes 64 hours after the first trans-
fection. Stable knockdown of CtBP1 was performed using shRNA
strategy using lentiviral construct with specific duplex sequences target-
ing CtBP1. DU145 and PC3 cell lines were used for stable CtBP1
knockdown. LCN2 and ARHGDIB were knocked down in stable
CtBP1 knockdown PC3 and DU145 cells. Sequence information of
all the siRNA used in this study has been given in the Supplementary
materials. Cell proliferation was determined using ATPase assay kit
(Promega) as described [23]. Additionally, cell proliferation was mea-
sured by cell counting. For this, 10,000 cells/well (DU145 and PC3)
were seeded in 24-well plates (n = 3), and cells were harvested and
counted at specified time points by Coulter counter (Beckman Coulter,
Fullerton, CA).
Basement Membrane Matrix Invasion Assay
For invasion assays, control shRNA stable cells or CtBP1 stable
knockdown cells as well as wild-type DU145 and PC3 cells were used.
Equal numbers of the indicated cells were seeded onto the basement
membrane matrix (BD Biosciences) present in the insert of a 24-well
culture plate. RPMI medium supplemented with 10% FBS was
added to the lower chamber as a chemoattractant. After 48 hours, non-
invading cells and extracellular matrix were removed with a cotton
swab. Invaded cells were stained with crystal violet and photographed.
The inserts were treated with 10% acetic acid, and absorbance was
measured at 560 nm.
Chromatin Immunoprecipitation Assay
The ChIP assays were performed as described [24]. Briefly, DU145
cells at 60% confluency were cross-linked with 1% formaldehyde for
10 minutes, followed by quenching with 0.125 M glycine for 5 min-
utes at room temperature. Cells were lysed and sonicated to frag-
ment the chromatin to an average size of 500 bp. This was followed
by overnight incubation with the antibodies and protein A or G mag-
netic beads. Cross-links were reversed by incubating chromatin at
62°C for 2 hours, and DNA was isolated. Tri-Methyl-Histone H3
(Lys4) antibody was obtained from Cell Signaling Technology,
Danvers, MA (Cat. No. 9751S). Rabbit IgG (Diagenode [Denville,
NJ], Cat. No. kch-504-250) was used as a control. Purified DNA
was analyzed by qPCR to determine fold enrichment relative to input
DNA. The primer sequences for the promoters analyzed are provided as
follows. Primers used for ChIP assay are LCN2: F, TGCAGAAATCTT-
GCCAAGTG and R, GGGATCTAGGGTGGGTTGAT; ARHGDIB:
F, CCCAGGGTTTCCTCTTCAA and R, TCAGTGCTTCACG-
TCTCTGTC; GAPDH: F, TACTAGCGGTTTTACGGGCG and
R, TCGAACAGGAGGAGCAGAGAGCGA.
Clonogenic Survival Assay
Clonogenic survival assays were performed using standard tech-
niques [25]. Cells were subcultured at clonal density immediately after
irradiation. Cell survival curves were fitted using the linear quadratic
equation, and the mean inactivation dose was calculated according to
the method of Fertil and Malaise [26].
Chicken Embryo Chorioallantoic Membrane Assay
Chicken embryo chorioallantoic membrane (CAM) assay was per-
formed as described previously [27]. To measure metastasis, we har-
vested lungs on day 18 of embryonic growth and analyzed for the
Figure 4. Role of CtBP1 in radiation resistance. Effects of CtBP1 knockdown on clonogenic survival of DU145 cells. (A) Stable clones of CtBP1
along with controls were radiated with clinically relevant doses of radiation and immediately plated for clonogenic survival. (B) Phospho-
H2AX immunoblot after radiation treatment of control and stable CtBP1 knockdown cells. GAPDH was used as a loading control.
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Figure 5. CtBP1 knockdown reduces prostate tumor growth in vivo. (A, B) Chicken CAM assay. Tumor growth was measured in CAM
models using DU145 and PC3 stable CtBP1 knockdown cells or control nontargeting shRNA stable cells. Tumors were harvested and
tumor weights were measured. (C) CtBP1 knockdown reduces metastasis of DU145 cells in CAM assay. Metastasized cells to the lungs
of chicken embryos were quantified using human Alu–specific PCR. (D) CtBP1 knockdown inhibits tumor growth in a mouse xenograft
model. Plot of mean tumor volume trajectories over time for the mice inoculated with CtBP1 stable knockdown pools (dotted line),
CtBP1 stable knockdown clone (broken line), and control (solid line) cells. Error bars represent SEM. (E) CtBP1 knockdown inhibits tumor
metastasis. PC3 luciferase stable CTBP1 knockdown or nontargeting control shRNA-treated cells were used in this study. At 2, 4, 6, and
8 weeks after transplantation, the establishment of metastases was followed by BLI. Data are representative of BLI of mice that had
developed metastases.
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presence of tumor cells by quantitative human Alu–specific PCR.
Genomic DNA from lungs was prepared using the Puregene DNA
purification system (Qiagen) and was quantified as previously described
[28]. For measuring tumor growth, embryos were sacrificed on day 18
and extraembryonic xenografts were excised and weighed.
Prostate Tumor Xenograft Model
All procedures involving mice were approved by the University
Committee on Use and Care of Animals at the University of Michigan
and conform to their relevant regulatory standards. To evaluate the
role of CtBP1 in tumor formation, we propagated stable CtBP1 knock-
down DU145 pools, single clone, and vector control cells and inocu-
lated 5 × 106 cells subcutaneously into the dorsal flank of 5-week-old
male nude athymic BALB/c nu/nu mice (n = 10 for each group;
Charles River Laboratory, Wilmington, MA). Tumor size was mea-
sured weekly, and tumor volumes were calculated using the formula
(π/6) (L × W 2), where L = length of tumor and W = width.
Murine Tumor Metastasis Models and
Bioluminescent Imaging
Experimental procedures were approved by the University Com-
mittee on Use and Care of Animals. Male CB17 severe combined
immunodeficient mice (4–6 weeks of age) were bred in-house. CtBP1
knockdown PC3-Luc cell pools or nontargeting shRNA-transduced
control cells were used for the metastasis model. Animals underwent
intracardiac injections of 200,000 cells and were imaged once weekly
by bioluminescent imaging (BLI) using a Xenogen IVIS 200 System
at the University of Michigan’s Center for Molecular Imaging as pre-
viously described [29]. Mice were injected with luciferin (100 μl at
40 mg/ml) by intraperitoneal injections. Ventral images were acquired
13 minutes after injection under 1.5% isoflurane anesthesia. Tumor
burden of each animal was determined with Living Image software
using regions of interest encompassing the entire animal. Animals with
no tumor take were defined as those with bioluminescent flux less than
1.151 × 106 p/s at week 8, and these animals were removed from sub-
sequent analysis. Statistical significance was determined using one-sided
two-sample t tests. Three animals closest in bioluminescent flux to each
group’s mean reading at week 8 were selected as representative images.
Results
CtBP1 Is Overexpressed in Metastatic Prostate Cancer
DNA microarray analysis indicated an up-regulation of CtBP1 in
metastatic prostate cancer (Figure 1A). To validate this observation,
we performed real-time qPCR using RNA from multiple prostate
cancer and benign tissue samples. Real-time qPCR analysis confirmed
the overexpression of CtBP1 in malignant prostate cancer tissues
relative to benign prostate samples (Figure 1B). We next performed
immunoblot analysis of prostate tissue using a CtBP1-specific mouse
monoclonal antibody. Results indicated increased CtBP1 protein
expression in metastatic prostate cancer relative to localized prostate
cancer or benign prostate tissues (Figure 1C ). Densitometric quan-
tification of the immunoblot indicated significant overexpression of
CtBP1 inmetastatic prostate cancer tissues (FigureW1A). Additionally,
CtBP1 was mainly localized to the nucleus (Figure 1D) in benign tis-
sue. However in aggressive prostate cancers, increased CtBP1 staining
was observed in the cytoplasm by immunohistochemistry analysis (Fig-
ure 1D). This observation was confirmed using an independent rabbit
polyclonal antibody against CtBP (Figure W1B). Immunostaining
using secondary antibody alone did not show any specific staining of
the prostate tissue (Figure W1C).
CtBP1 Is Involved in Prostate Cancer Cell Proliferation
and Invasion
Because CtBP1 is known to play an oncogenic role in other cancers,
we examined the role of CtBP1 in prostate cancer cell proliferation and
invasion. We used both transient RNA interference as well as stable
knockdown strategy specifically targeting CtBP1 in aggressive prostate
cell lines DU145 and PC3. The transient and stable knockdown
of CtBP1 were confirmed by immunoblot analysis (Figures 2A and
W2A). Using a commercially available cell proliferation assay reagent
Cell Titer-Glo (Promega), we observed a decrease in cell proliferation
on both transient and stable knockdown of CtBP1 relative to control
cells (Figures 2, B and C , and W2B). Likewise, knockdown of CtBP1
in prostate cancer cells reduced the ability of these cancer cells to invade
in a Boyden chamber matrigel invasion assay (Figures 2, D and E ,
and W2C ). Together, these observations support the involvement of
CtBP1 in the proliferation and invasion of prostate cancer cells in vitro.
Regulation of Gene Expression by CtBP1 in Prostate
Cancer Cells
To dissect the functional role of CtBP1 in prostate cancer progression
and transcriptional repression in prostate cancer cells, we performed
global gene expression analysis using RNA from CtBP1 knockdown
prostate cell lines. We generated stable CtBP1 knockdown DU145,
PC3, and LNCaP prostate cancer cell lines using lentivirus-based
shRNA. We identified multiple molecular targets of CtBP1 that be-
came activated on CtBP1 knockdown including tumor suppressors
and metastasis suppressors (Figure 3A and Table W1). We validated
the reactivation of known CtBP1 repression target E-cadherin in
CtBP1 knockdown cells (Figure 3B) as well as novel targets LCN2
and ARHGDIB (RhoGDI2) that are implicated in invasion and metas-
tasis suppression [30,31] (Figures 3, C and D, and W3, A and B).
Chromatin immunoprecipitation analysis at the promoter region of
these genes in CtBP1 stable knockdown cells suggested an increase in
the activating histone H3–trimethyl lysine 4 methylation mark com-
pared to control GAPDH (Figure W3, C–E ). Additionally, we per-
formed the knockdown of the reactivated LCN2 in PC3-CtBP1 stable
knockdown cell lines using two independent duplex targeting LCN2
(Figure 3E ). Whereas knockdown of CtBP1 reduced the invasion
along with reactivation of LCN2, subsequent knockdown of LCN2 in
these cells led to reversion to invasive phenotype (Figure 3F), indicating
a critical role for LCN2 in CtBP1-mediated invasion.
Knockdown of CtBP1 Renders Prostate Cancer Cells
Sensitive to Radiation
CtBP1 has been shown to play a role in chemoresistance in breast
cancer cells [32]. Furthermore, homeodomain-interacting protein
kinase 2 is known to phosphorylate CtBP1, leading to its degradation
on UV stimulation and causing apoptosis of cells [33,34]. To deter-
mine if CtBP1 also plays a role in regulating radiation resistance and
DNA damage repair processes, we assessed the effect of CtBP1 on
radiation-induced cell death. CtBP1 knockdown DU145 cells showed
considerable reduction in clonogenic survival fraction (enhancement
ratio, 1.4 ± 0.15) (Figure 4A), which correlated with the slower resolu-
tion of H2AX phosphorylation (Figure 4B).
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CtBP1 Is Essential for Prostate Tumor Growth and Metastasis
To study the effect of CtBP1 on tumor growth and metastasis
in vivo, we employed a chicken CAM model. CAM was performed
as described previously [27] using CtBP1 knockdown DU145 and
PC3 prostate cancer cells. Depletion of CtBP1 results in significantly
reduced tumor weight compared to nontarget transfected control cells
in both DU145 and PC3 cells (Figure 5, A and B). Further, the lungs
of chicken embryos displayed attenuated metastasis in the CtBP1
knockdown group compared to the control group (Figure 5C).
We next examined CtBP1-mediated tumorigenesis in a murine
xenograft model. Single clone of CtBP1 knockdown cells as well as
pooled CtBP1 knockdown DU145 cells showed significantly reduced
tumor growth in mice (Figure 5D). We also employed a murine me-
tastasis model using PC3 luciferase cells. CtBP1 stable knockdown in
PC3 luciferase cells was confirmed by qPCR as well as immunoblot
analysis (Figure W4A). Mice injected with CtBP1 knockdown pros-
tate cancer cells showed reduced metastasis compared to nontarget-
ing shRNA-transduced control PC3 luciferase cells (Figures 5E and
W4B). These data provide compelling evidence for critical role of
CtBP1 in prostate tumor growth and metastasis.
Discussion
In this study, we measured the expression level of transcriptional
corepressor CtBP1 in prostate cancer and investigated the mechanism
of its oncogenic action. It is becoming increasingly clear that dys-
regulated transcriptional repression plays a crucial role in tumorigenesis.
Several epigenetic modifiers including HDACs and PcG proteins
mediate transcriptional repression in cancer cells through posttransla-
tional modification of histones. CtBP1 is known to act as a corepressor
that binds to histone modifiers such as HDACs, G9A, as well as LSD1
[35] and recruits repressive complexes to promoters of tumor sup-
pressors to inhibit their expression. Our study uncovers the role of
CtBP1 in prostate cancer progression and its molecular targets. We
demonstrated the overexpression and mislocalization of CtBP1 to
cytoplasm in aggressive prostate cancers. The mechanism of CtBP1
mislocalization in aggressive cancer and the functional significance of
cytoplasmic CtBP1 are yet to be elucidated. CtBP1 acts as a transcrip-
tional repressor in prostate cancer, and gene expression profiling studies
using multiple prostate cancer cell lines indicated derepression of
numerous target genes on CtBP1 knockdown, many of which are
tumor suppressors. Rescue experiments underscored the role of these
transcriptional targets in prostate cancer progression. Moreover, LCN2,
a target of CtBP1-mediated repression is known to function as an in-
vasion and angiogenesis suppressor in pancreatic cancer [30]. Mice
injected with MIAPaCa-2 pancreatic cells overexpressing LCN2 showed
reduced tumor volume, local and distant metastasis, and angiogenesis.
Our data show that LCN2 plays a similar role in prostate cancer cells.
A recent study has shown that ARHGDIB, identified here as a CtBP1-
mediated repression target, reduces tumor metastasis by altering in-
flammation in the tumor microenvironment [36]. Our in vitro and
in vivo studies suggest that these targets are involved in CtBP1-mediated
oncogenesis in prostate cancer cells. Knockdown of CtBP1 sensitized
DU145 cells to radiation, suggesting an important role for CtBP1 in
radiation-induced DNA repair. Interestingly, our preliminary mass
spectrometry data suggest that CtBP1 binds to DNA damage repair
pathway proteins (Varambally et al., unpublished observations). Impor-
tantly, these results have implications for patient overexpressing CtBP1
that undergo radiation therapy.
Here, we propose a model of CtBP1-mediated corepression and
tumor suppressor axis in prostate cancer, wherein CtBP1 represses
multiple tumor suppressors in prostate cancer. However, further studies
are required to elucidate the mechanism of CtBP1-mediated radiation
resistance to determine whether CtBP1 overexpression predicts aggres-
sive disease and if it has a functional role in the cytoplasm. The NAD-
dependent dehydrogenase activity of CtBP1 makes it an attractive
therapeutic target. Small-molecule inhibitors targeting CtBP1 enzy-
matic activity or its interaction with downstream targets and binding
proteins could potentially serve as an effective strategy to inhibit its
oncogenic activity.
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Table W1. List of Genes Altered by CtBP1 Knockdown in Prostate Cancer Cells.
Gene Name Direction Fold Change
LCN2 Up 11.03372089
SAA1 Up 10.62440645
SLC6A14 Up 10.3697991
THC2682885 Up 8.499569184
SAA4 Up 8.218110514
SAA2 Up 7.998343841
THC2650074 Up 6.757080752
THC2650501 Up 6.629116935
SERPINB3 Up 6.492061322
DAPP1 Up 6.312501496
UBD Up 6.252205533
C10orf10 Up 6.20416844
ACTL8 Up 5.728690584
PDZK1IP1 Up 5.41349766
EDN1 Up 5.312535078
NOD2 Up 5.271836541
C10orf10 Up 5.010336999
ST6GALNAC5 Up 4.924610899
SLPI Up 4.714816831
SLC6A12 Up 4.699978694
DENND2A Up 4.695348901
SAA3P Up 4.656360545
GBP4 Up 4.644158877
KLK10 Up 4.419614789
KLRC2 Up 4.399289221
SCGB2A1 Up 4.372932373
PDZK1IP1 Up 4.328325248
CHI3L2 Up 4.312129669
SLPI Up 4.254349021
COP1 Up 4.222383184
FAM26B Up 4.182196359
VNN1 Up 4.028550143
SERPINB4 Up 3.993168302
C3 Up 3.959253087
C1orf167 Up 3.949487904
A_23_P77389 Up 3.894306375
ENST00000372493 Up 3.77246666
ENST00000369783 Up 3.721224797
ETV7 Up 3.618856373
OASL Up 3.592721037
KLRC1 Up 3.575376247
A_32_P167111 Up 3.549373992
CASP1 Up 3.53112085
EDN2 Up 3.518170121
AY927488 Up 3.506095338
CSPG4 Up 3.488841263
BMF Up 3.419565273
BIK Up 3.412660642
RHOV Up 3.398891204
A_23_P247 Up 3.395778679
SERPINA3 Up 3.37938261
NEURL Up 3.34920203
KLK10 Up 3.338074193
HS3ST1 Up 3.270192482
THC2582296 Up 3.227026308
FLJ13744 Up 3.223450915
CTSS Up 3.213339698
LOH11CR2A Up 3.183020595
C1QTNF5 Up 3.169958498
KRT16 Up 3.106029197
IL23A Up 3.053823822
KRT16 Up 3.031365254
TMEM92 Up 2.99350621
APOL3 Up 2.990667894
RHOV Up 2.965110679
SPRR1A Up 2.963827972
S100A4 Up 2.96284402
BM723547 Up 2.95591769
PRICKLE2 Up 2.926055588
IGF2 Up 2.893507103
LOC254848 Up 2.866625949
AZGP1 Up 2.865917344
CARD6 Up 2.86345534
Table W1. (continued )
Gene Name Direction Fold Change
ARL14 Up 2.845714686
A_32_P20040 Up 2.824936081
RHBDL2 Up 2.824004231
TRAF1 Up 2.801123087
POU2F3 Up 2.787456539
CEACAM1 Up 2.781567452
GPR20 Up 2.742585123
KSR1 Up 2.73469618
ELF3 Up 2.723674882
FHAD1 Up 2.723599976
GBP5 Up 2.716484367
A_32_P40673 Up 2.715719853
MSTP9 Up 2.709864821
APOL3 Up 2.709100778
LINCR Up 2.699925499
A_32_P153361 Up 2.69165116
YPEL2 Up 2.677090933
INCA Up 2.668568056
ARHGDIB Up 2.660968084
COL16A1 Up 2.659553097
CSTA Up 2.65303983
LEF1 Up 2.651075658
ACVRL1 Up 2.647718605
NTF5 Up 2.644979171
SDCBP2 Up 2.643978408
C1orf167 Up 2.640432821
LY96 Up 2.627523781
FLJ22675 Up 2.625238807
SP8 Up 2.615780109
DENND2A Up 2.609905282
MARCO Up 2.60692239
ADRA1B Up 2.602117819
CCL3 Up 2.598626493
TNFSF15 Up 2.597525144
NFE2 Up 2.595618858
DLL1 Up 2.594785429
HLA-DMA Up 2.593241301
MYL9 Up 2.59106039
FN1 Up 2.587362245
MMP19 Up 2.585415317
SDC4 Up 2.58044802
KNDC1 Up 2.575092752
B3GALT4 Up 2.574645428
YPEL2 Up 2.574150346
CARD14 Up 2.57094572
CLIC3 Up 2.561894522
C1orf116 Up 2.55762971
ADORA2A Up 2.54337386
AB014766 Up 2.531727802
LYPLA2 Up 2.530422216
KRT14 Up 2.521067012
ARG2 Up 2.511097922
AP1M2 Up 2.506939054
FOXO4 Up 2.503068888
AL080205 Down 0.399113121
ADAMTS15 Down 0.395735507
MBD5 Down 0.393249606
EDG7 Down 0.388723832
AA581414 Down 0.383696657
A_24_P915566 Down 0.382915063
AF090920 Down 0.381286744
PGA5 Down 0.376015457
ARL11 Down 0.365791354
CTBP1 Down 0.362998695
SLC7A11 Down 0.362424314
ENST00000327625 Down 0.361342653
ADAM7 Down 0.355771403
A_24_P922440 Down 0.345827631
KLF17 Down 0.333723905
CTBP1 Down 0.325783221
BMPR1B Down 0.323357446
GIPR Down 0.315843641
LOC348174 Down 0.299451578
Table W1. (continued )
Gene Name Direction Fold Change
C3orf50 Down 0.298466301
AF334588 Down 0.297229095
PBX1 Down 0.257104943
C13orf21 Down 0.255784914
ENST00000259289 Down 0.251085668
KIAA1199 Down 0.228711041
C12orf42 Down 0.217435692
LOC152573 Down 0.212965398
AK021467 Down 0.199419469
Figure W1. (A) Densitometric scanning analysis of prostate tissue CtBP1 expression. Each point represents a tissue sample. (B) Expression
and localization of CtBP1 protein in prostate cancer. Immunohistochemical analysis of CtBP1 in prostate cancer. (C) Immunohistochemical
staining of prostate tissues with secondary antibody alone.
Figure W2. Transient knockdown of CtBP1 reduces cell proliferation and inhibits invasion. (A) Immunoblot analysis using lysates from pros-
tate cell lines DU145 and PC3 treated with two independent CtBP1-specific siRNA duplex on nontarget control duplex. β-Actin was used as
control. (B) Cell proliferation was measured using cells transfected with CtBP1 siRNA duplex or control nontargeting siRNA using PC3 cells.
(C) DU145 and PC3 cells were treated with two CtBP1-specific siRNA duplex and control duplex, and Boyden chamber matrigel invasion
assay was performed. Nontargeting siRNA served as control. Invaded cells were stained, and absorbance was measured.
Figure W3. CtBP1 regulates gene expression. (A and B) ARHGDIB expression in stable CtBP1 knockdown DU145 and PC3 cells. (C and D)
Chromatin immunoprecipitation experiments indicate increased HeK4me3 trimethylation mark at the promoters of LCN2 and ARHGDIB on
knockdown of CtBP1. (E) GAPDH promoter did not show altered HeK4me3.
Figure W4. Role of CtBP1 metastasis. (A) Real-time qPCR and immunoblot of CtBP1 stable knockdown PC3 luciferase cells. (B) Represen-
tative bioluminescent images of mice inoculated with control PC3 luciferase cells and CtBP1 stable knockdown PC3 luciferase cells.
